Goldman Sachs analyst Caitlin Burrows lowered the firm’s price target on Lineage (LINE) to $89 from $104 but keeps a Buy rating on the shares after its Q3 results. The company’s Q3 net operating ...

Bobby Allison, founder of racing's "Alabama Gang" and a NASCAR Hall of Famer, died Saturday. He was 86. NASCAR released a ...

President Joe Biden’s administration on Friday proposed tighter restrictions on oil, solar and wind energy development across more than 6,500 square miles of federal land in the U.S. West to protect a ...

The elusive wisdom of a Chinese sage is widely quoted but challenging to understand. Each new translation confronts its ...

The new DG5000 Pro Series Arbitrary Waveform Generators bring performance and value to applications including embedded ...

If you type “laptops under $500” into any search bar ... For example, we found that in our tests, Intel’s latest Iris Xe line of processors with integrated graphics can run some of the ...

Megacap tech stocks are still "the tail wagging the dog," said Rob Williams, chief investment strategist at Sage Advisory ...

Welcome to Sage Therapeutics’ Third Quarter 2024 Financial ... Last year, we set a goal to establish ZURZUVAE as a first-line therapy and standard of care for women with PPD.

Sage Therapeutics, Inc. SAGE reported a loss of $1.53 per share for the third quarter of 2024, wider than the Zacks Consensus Estimate of a loss of $1.52. The company had reported a loss of $2.81 ...

Sage Therapeutics shares have lost about 60.6% since the beginning of the year versus the S&P 500's gain of 22.1% ... So, the shares are expected to perform in line with the market in the near future.

Sage Therapeutics shares have lost about 60.6% since the beginning of the year versus the S&P 500's gain of 22.1% ... So, the shares are expected to perform in line with the market in the near ...